AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|December 7, 2009
Pharma Unplugged: Episode# 2- Layoffs & Bonuses
Reid Paul, Editor-in-Chief of Pharmaceutical Representative Magazine joins host George Koroneos to discuss the top five pharmaceutical industry news stories of the week
Advertisement
Layoffs & Bonuses
Pharma Unplugged Podcast Series
Recorded: 12/3/2009
Air Date: 12/7/2009
Host: George Koroneos, Pharm Exec
Cohost: Reid Paul, Pharm Rep Magazine
Download Adobe Flash Player
This week we discuss:
- Pfizer’s medical education relationship with the Canadian Medical Association
- Journalists take FDA to task for not being transparent enough
- Layoffs and job cuts at Sanofi-Aventis
- New report shows that DTC receives more funding than sales calls in certain drug categories
- CEO compensation bump in life science
Sponsors
Patient Segmentation Strategies
WEBCAST – Sponsor (Medpoint)
How Virtual Media Can Save the Medical Speaker Program
WEBCAST – Sponsor (Healthgrades)
Driving Medication Compliance
PODCAST – Sponsor (AdherenceRx)
Episode# 1
A Link Apart : FDA Social Media Hearing
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
5